공시 • Apr 21
Beacon Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 27, 2026 Beacon Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 27, 2026 공시 • Jan 22
Beacon Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026 Beacon Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026 공시 • Nov 07
Beacon Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 11, 2025 Beacon Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 11, 2025 공시 • Oct 24
Beacon Pharmaceuticals PLC announces Annual dividend, payable on January 22, 2026 Beacon Pharmaceuticals PLC announced Annual dividend of BDT 2.1000 per share payable on January 22, 2026, ex-date on November 17, 2025 and record date on November 16, 2025. 공시 • Oct 23
Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025 Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025, at 11:00 Central Asia Standard Time. Location: hybrid platform., Bangladesh 공시 • Oct 21
Beacon Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 22, 2025 Beacon Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 22, 2025 공시 • Apr 23
Beacon Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 29, 2025 Beacon Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 29, 2025 공시 • Jan 20
Beacon Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 29, 2025 Beacon Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 29, 2025 공시 • Oct 25
Beacon Pharmaceuticals PLC to Report Q1, 2025 Results on Oct 29, 2024 Beacon Pharmaceuticals PLC announced that they will report Q1, 2025 results on Oct 29, 2024 Upcoming Dividend • Oct 21
Upcoming dividend of ৳2.00 per share Eligible shareholders must have bought the stock before 28 October 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 56% but the company is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of Bangladeshi dividend payers (4.8%). Lower than average of industry peers (3.6%). Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ৳113, the stock trades at a trailing P/E ratio of 56x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 50% over the past three years. 공시 • Oct 01
Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024 Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024, at 11:00 Central Asia Standard Time. 공시 • Sep 19
Beacon Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Sep 29, 2024 Beacon Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Sep 29, 2024 Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ৳137, the stock trades at a trailing P/E ratio of 68.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 37% over the past three years. Reported Earnings • May 18
Third quarter 2024 earnings released: ৳0.95 loss per share (vs ৳0.037 loss in 3Q 2023) Third quarter 2024 results: ৳0.95 loss per share (further deteriorated from ৳0.037 loss in 3Q 2023). Revenue: ৳2.64b (up 23% from 3Q 2023). Net loss: ৳220.3m (loss widened ৳211.6m from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. 공시 • May 08
Beacon Pharmaceuticals PLC to Report Q3, 2024 Results on May 12, 2024 Beacon Pharmaceuticals PLC announced that they will report Q3, 2024 results on May 12, 2024 New Risk • Apr 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (7.0% net profit margin). New Risk • Feb 14
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). High level of non-cash earnings (27% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (7.0% net profit margin). 공시 • Jan 30
Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary Beacon Pharmaceuticals PLC has informed that the Board of Directors has appointed Mr. Md. Sahabuddin FCS as the Company Secretary of the Company with immediate effect. 공시 • Jan 26
Beacon Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024 Beacon Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024 Reported Earnings • Jan 25
First quarter 2024 earnings released: EPS: ৳1.60 (vs ৳0.99 in 1Q 2023) First quarter 2024 results: EPS: ৳1.60 (up from ৳0.99 in 1Q 2023). Revenue: ৳2.32b (up 15% from 1Q 2023). Net income: ৳369.5m (up 62% from 1Q 2023). Profit margin: 16% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings. Reported Earnings • Dec 07
Full year 2023 earnings released: EPS: ৳2.21 (vs ৳4.05 in FY 2022) Full year 2023 results: EPS: ৳2.21 (down from ৳4.05 in FY 2022). Revenue: ৳8.51b (up 6.1% from FY 2022). Net income: ৳509.8m (down 46% from FY 2022). Profit margin: 6.0% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Nov 20
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (101% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Profit margins are more than 30% lower than last year (8.6% net profit margin). Upcoming Dividend • Nov 12
Upcoming dividend of ৳1.60 per share at 0.7% yield Eligible shareholders must have bought the stock before 19 November 2023. Payment date: 23 January 2024. Payout ratio is a comfortable 39% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%). 공시 • Nov 08
Beacon Pharmaceuticals PLC to Report Q1, 2024 Results on Nov 13, 2023 Beacon Pharmaceuticals PLC announced that they will report Q1, 2024 results on Nov 13, 2023 공시 • Oct 26
Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023 Beacon Pharmaceuticals PLC has recommended 16% Cash Dividend for the year ended June 30, 2023. 공시 • Oct 24
Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023 Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023, at 11:00 Bangladesh Standard Time. 공시 • Oct 17
Beacon Pharmaceuticals PLC to Report Q3, 2023 Results on Oct 22, 2023 Beacon Pharmaceuticals PLC announced that they will report Q3, 2023 results on Oct 22, 2023 공시 • Jun 20
Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial Officer Beacon Pharmaceuticals PLC announced that the Board of Directors has appointed Mr. Md. Jalal Uddin, FCA as Chief Financial Officer of the company with effect from June 06, 2023. Reported Earnings • May 07
Third quarter 2023 earnings released: ৳0.037 loss per share (vs ৳0.99 profit in 3Q 2022) Third quarter 2023 results: ৳0.037 loss per share (down from ৳0.99 profit in 3Q 2022). Revenue: ৳2.15b (up 16% from 3Q 2022). Net loss: ৳8.66m (down 104% from profit in 3Q 2022). Reported Earnings • Feb 17
Second quarter 2023 earnings released: EPS: ৳1.61 (vs ৳1.07 in 2Q 2022) Second quarter 2023 results: EPS: ৳1.61 (up from ৳1.07 in 2Q 2022). Revenue: ৳2.19b (up 5.5% from 2Q 2022). Net income: ৳370.9m (up 51% from 2Q 2022). Profit margin: 17% (up from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Dec 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mohammad Sanaullah was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 24
First quarter 2023 earnings released: EPS: ৳0.99 (vs ৳1.52 in 1Q 2022) First quarter 2023 results: EPS: ৳0.99 (down from ৳1.52 in 1Q 2022). Revenue: ৳2.02b (down 11% from 1Q 2022). Net income: ৳228.8m (down 35% from 1Q 2022). Profit margin: 11% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Oct 27
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022 The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 16% cash dividend for the year ended on June 30, 2022. Valuation Update With 7 Day Price Move • Sep 25
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ৳315, the stock trades at a trailing P/E ratio of 77.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,087% over the past three years. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 24% share price gain to ৳320, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,040% over the past three years. Reported Earnings • May 22
Third quarter 2022 earnings released: EPS: ৳0.99 (vs ৳2.01 in 3Q 2021) Third quarter 2022 results: EPS: ৳0.99 (down from ৳2.01 in 3Q 2021). Revenue: ৳1.84b (down 29% from 3Q 2021). Net income: ৳228.9m (down 51% from 3Q 2021). Profit margin: 12% (down from 18% in 3Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 12
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: EPS: ৳1.07 (up from ৳1.02 in 2Q 2021). Revenue: ৳2.08b (down 4.8% from 2Q 2021). Net income: ৳246.3m (up 5.1% from 2Q 2021). Profit margin: 12% (up from 11% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Dec 14
Upcoming dividend of ৳1.50 per share Eligible shareholders must have bought the stock before 21 December 2021. Payment date: 30 January 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.8%). Reported Earnings • Jun 24
Third quarter 2020 earnings released: EPS ৳0.25 (vs ৳0.20 in 3Q 2019) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 25
New 90-day high: ৳103 The company is up 50% from its price of ৳68.20 on 26 November 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. Is New 90 Day High Low • Feb 01
New 90-day high: ৳84.30 The company is up 5.0% from its price of ৳80.00 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period. Is New 90 Day High Low • Nov 30
New 90-day low: ৳66.50 The company is down 17% from its price of ৳79.80 on 01 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Reported Earnings • Nov 26
Third quarter 2020 earnings released: EPS ৳0.25 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. 공시 • Jul 07
Beacon Pharmaceuticals Ltd. to Report Q3, 2020 Results on Jun 25, 2020 Beacon Pharmaceuticals Ltd. announced that they will report Q3, 2020 results on Jun 25, 2020